ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?

Published on 19 Feb 2025 on Zacks · via Yahoo Finance

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance...

Read the rest of the article

Start tracking your investments with Statfolio

PCRX beat earnings estimates in two of the trailing four quarters, met once and missed in the oth...

Zacks · via Yahoo Finance 21 Feb 2025

, opens new tab genetic disorder drug on Friday, making it the first treatment for a rare conditi...

Reuters 21 Feb 2025

On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performan...

Zacks · via Yahoo Finance 19 Feb 2025

The United States market has shown a positive trend, rising 1.2% over the last week and 24% over ...

Simply Wall St. · via Yahoo Finance 19 Feb 2025

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is possibly approaching a major achievement in its...

Simply Wall St. · via Yahoo Finance 26 Dec 2024

Key Insights Mirum Pharmaceuticals' Annual General Meeting to take place on 5th of JuneTotal pay ...

Simply Wall St. via Yahoo Finance 30 May 2024

With the business potentially at an important milestone, we thought we'd take a closer look at Mi...

Simply Wall St. via Yahoo Finance 28 May 2024

Mirum Pharmaceuticals, Inc. MIRM incurred first-quarter 2024 loss of 54 cents per share, wider th...

Zacks via Yahoo Finance 9 May 2024

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) recently announced the publication of the Phase 3...

Investing.com 7 May 2024

Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals Inc (NASDAQ:MIRM),...

GuruFocus.com via Yahoo Finance 26 Mar 2024